| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 28 | 2024 | 1720 | 1.610 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 8 | 2024 | 111 | 1.190 |
Why?
|
| Androgen Antagonists | 8 | 2024 | 144 | 0.710 |
Why?
|
| Receptors, Androgen | 2 | 2017 | 113 | 0.580 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2016 | 128 | 0.530 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2022 | 2436 | 0.500 |
Why?
|
| Fatigue | 5 | 2011 | 174 | 0.430 |
Why?
|
| Bone Neoplasms | 4 | 2019 | 322 | 0.390 |
Why?
|
| Prostate-Specific Antigen | 8 | 2024 | 352 | 0.350 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 2018 | 40 | 0.320 |
Why?
|
| Hypercalcemia | 10 | 1990 | 59 | 0.300 |
Why?
|
| Male | 45 | 2024 | 40956 | 0.290 |
Why?
|
| Antineoplastic Agents | 7 | 2019 | 2357 | 0.280 |
Why?
|
| Quality of Life | 9 | 2022 | 1583 | 0.270 |
Why?
|
| Testosterone | 4 | 2024 | 271 | 0.260 |
Why?
|
| 5-alpha Reductase Inhibitors | 2 | 2014 | 7 | 0.240 |
Why?
|
| Taxoids | 3 | 2015 | 129 | 0.240 |
Why?
|
| Thrombin | 1 | 2003 | 61 | 0.220 |
Why?
|
| Surveys and Questionnaires | 6 | 2013 | 2501 | 0.220 |
Why?
|
| Prednisone | 4 | 2024 | 258 | 0.210 |
Why?
|
| Aged, 80 and over | 14 | 2019 | 6501 | 0.210 |
Why?
|
| Aged | 23 | 2019 | 18402 | 0.210 |
Why?
|
| Mice, Nude | 16 | 2014 | 790 | 0.200 |
Why?
|
| Lung Neoplasms | 15 | 2003 | 2261 | 0.190 |
Why?
|
| Carcinoma, Squamous Cell | 11 | 2003 | 1075 | 0.190 |
Why?
|
| Metformin | 1 | 2022 | 128 | 0.190 |
Why?
|
| Humans | 51 | 2024 | 86601 | 0.190 |
Why?
|
| Neoplasm Metastasis | 10 | 2018 | 1056 | 0.180 |
Why?
|
| Radium | 1 | 2019 | 7 | 0.180 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2023 | 382 | 0.170 |
Why?
|
| Middle Aged | 23 | 2019 | 25017 | 0.170 |
Why?
|
| Etidronic Acid | 2 | 1991 | 5 | 0.170 |
Why?
|
| Kallikreins | 1 | 2017 | 47 | 0.160 |
Why?
|
| Carcinoma, Renal Cell | 2 | 1994 | 426 | 0.150 |
Why?
|
| Neoplasms | 4 | 2007 | 2897 | 0.150 |
Why?
|
| Cost of Illness | 1 | 2018 | 150 | 0.150 |
Why?
|
| Finasteride | 3 | 2013 | 8 | 0.150 |
Why?
|
| Pain | 3 | 2010 | 391 | 0.150 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 52 | 0.150 |
Why?
|
| Orchiectomy | 3 | 2011 | 68 | 0.140 |
Why?
|
| Kidney Neoplasms | 2 | 1994 | 621 | 0.140 |
Why?
|
| Urination Disorders | 2 | 2013 | 50 | 0.140 |
Why?
|
| BRCA2 Protein | 1 | 2016 | 158 | 0.140 |
Why?
|
| DNA Repair | 1 | 2017 | 356 | 0.130 |
Why?
|
| BRCA1 Protein | 1 | 2016 | 200 | 0.130 |
Why?
|
| Decorin | 1 | 2014 | 5 | 0.130 |
Why?
|
| Oncolytic Viruses | 1 | 2014 | 23 | 0.130 |
Why?
|
| Calcium | 9 | 2008 | 1156 | 0.130 |
Why?
|
| Oncolytic Virotherapy | 1 | 2014 | 41 | 0.130 |
Why?
|
| Neoplasm Transplantation | 11 | 2014 | 391 | 0.130 |
Why?
|
| Echinomycin | 1 | 1994 | 2 | 0.120 |
Why?
|
| Thioguanine | 1 | 1994 | 17 | 0.120 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2014 | 18 | 0.120 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 329 | 0.120 |
Why?
|
| Androgens | 4 | 2024 | 167 | 0.120 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2000 | 236 | 0.120 |
Why?
|
| Naphthalenes | 1 | 2014 | 45 | 0.120 |
Why?
|
| Urinary Bladder Neck Obstruction | 1 | 2013 | 21 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2015 | 279 | 0.110 |
Why?
|
| Imidazoles | 1 | 2014 | 162 | 0.110 |
Why?
|
| Prostate | 1 | 2016 | 377 | 0.110 |
Why?
|
| Pharmacogenetics | 1 | 2016 | 434 | 0.110 |
Why?
|
| Biomarkers, Tumor | 2 | 2017 | 1464 | 0.100 |
Why?
|
| Prothrombin | 2 | 2003 | 18 | 0.100 |
Why?
|
| Adenocarcinoma | 3 | 2015 | 1169 | 0.100 |
Why?
|
| Cell Line, Tumor | 3 | 2014 | 2426 | 0.100 |
Why?
|
| Cholestenone 5 alpha-Reductase | 1 | 2010 | 2 | 0.100 |
Why?
|
| Blood Coagulation | 2 | 2003 | 91 | 0.100 |
Why?
|
| Urinary Incontinence | 1 | 2013 | 206 | 0.100 |
Why?
|
| Genomics | 1 | 2016 | 720 | 0.100 |
Why?
|
| Enzyme Inhibitors | 2 | 2010 | 639 | 0.090 |
Why?
|
| Mitoxantrone | 1 | 2010 | 68 | 0.090 |
Why?
|
| Mice | 17 | 2014 | 11352 | 0.090 |
Why?
|
| Peptide Fragments | 3 | 2003 | 460 | 0.090 |
Why?
|
| Survival Rate | 5 | 2015 | 1860 | 0.090 |
Why?
|
| Arabinonucleotides | 1 | 1989 | 3 | 0.090 |
Why?
|
| Vidarabine Phosphate | 1 | 1989 | 5 | 0.090 |
Why?
|
| Sulfonamides | 1 | 2011 | 300 | 0.090 |
Why?
|
| Hormones | 3 | 2022 | 140 | 0.090 |
Why?
|
| Cisplatin | 4 | 2000 | 612 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2010 | 150 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2011 | 370 | 0.080 |
Why?
|
| Ergocalciferols | 1 | 2008 | 38 | 0.080 |
Why?
|
| Nitriles | 2 | 2022 | 149 | 0.080 |
Why?
|
| Treatment Outcome | 7 | 2018 | 7988 | 0.080 |
Why?
|
| Cell Cycle | 1 | 2010 | 502 | 0.080 |
Why?
|
| Anorexia | 1 | 2007 | 30 | 0.080 |
Why?
|
| Trans-Activators | 1 | 2010 | 429 | 0.080 |
Why?
|
| Psychometrics | 2 | 2010 | 327 | 0.080 |
Why?
|
| Epidermal Growth Factor | 1 | 1987 | 119 | 0.070 |
Why?
|
| Neoplasm Staging | 4 | 2014 | 1937 | 0.070 |
Why?
|
| Adult | 11 | 2017 | 25640 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 864 | 0.070 |
Why?
|
| Thiadiazoles | 1 | 1986 | 12 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 592 | 0.070 |
Why?
|
| Disease Models, Animal | 6 | 2014 | 2232 | 0.070 |
Why?
|
| Animals | 18 | 2014 | 26581 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2010 | 696 | 0.070 |
Why?
|
| Fluorouracil | 2 | 2000 | 556 | 0.070 |
Why?
|
| Plicamycin | 1 | 1985 | 9 | 0.070 |
Why?
|
| Factor Analysis, Statistical | 1 | 2005 | 111 | 0.060 |
Why?
|
| Stress, Psychological | 1 | 2007 | 313 | 0.060 |
Why?
|
| Abiraterone Acetate | 1 | 2024 | 11 | 0.060 |
Why?
|
| Carcinoma, Small Cell | 1 | 1985 | 134 | 0.060 |
Why?
|
| Castration | 1 | 2024 | 41 | 0.060 |
Why?
|
| Time Factors | 5 | 2018 | 5209 | 0.060 |
Why?
|
| Administration, Intravesical | 1 | 2023 | 33 | 0.060 |
Why?
|
| Registries | 2 | 2018 | 702 | 0.060 |
Why?
|
| BCG Vaccine | 1 | 2023 | 31 | 0.060 |
Why?
|
| Vinblastine | 1 | 2003 | 108 | 0.060 |
Why?
|
| Health Surveys | 1 | 2003 | 239 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2023 | 172 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2003 | 1074 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 4 | 2014 | 1047 | 0.050 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2022 | 18 | 0.050 |
Why?
|
| Dutasteride | 2 | 2013 | 5 | 0.050 |
Why?
|
| Azasteroids | 2 | 2013 | 5 | 0.050 |
Why?
|
| Mifepristone | 1 | 2022 | 33 | 0.050 |
Why?
|
| Phenylthiohydantoin | 1 | 2022 | 41 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2010 | 2705 | 0.050 |
Why?
|
| Amino Acids | 1 | 2003 | 252 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2003 | 256 | 0.050 |
Why?
|
| Parathyroid Hormone | 4 | 1990 | 218 | 0.050 |
Why?
|
| Benzamides | 1 | 2022 | 229 | 0.050 |
Why?
|
| Female | 10 | 2019 | 44507 | 0.050 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2022 | 120 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2003 | 407 | 0.050 |
Why?
|
| Dihydrotestosterone | 2 | 2010 | 27 | 0.050 |
Why?
|
| Etoposide | 1 | 2000 | 196 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2016 | 1538 | 0.050 |
Why?
|
| Injections, Subcutaneous | 2 | 1991 | 117 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 879 | 0.040 |
Why?
|
| Carboplatin | 2 | 2015 | 286 | 0.040 |
Why?
|
| Drug Evaluation | 3 | 1989 | 141 | 0.040 |
Why?
|
| United States | 3 | 2018 | 6665 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 894 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2022 | 770 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2000 | 276 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2017 | 25 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2018 | 21 | 0.040 |
Why?
|
| Bone and Bones | 2 | 1990 | 265 | 0.040 |
Why?
|
| Androstenes | 1 | 2017 | 43 | 0.040 |
Why?
|
| Interviews as Topic | 2 | 2010 | 319 | 0.040 |
Why?
|
| Antibodies | 2 | 1990 | 350 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2017 | 72 | 0.040 |
Why?
|
| Benzimidazoles | 1 | 2017 | 140 | 0.040 |
Why?
|
| Cell Line | 3 | 1991 | 2468 | 0.040 |
Why?
|
| Biomarkers | 1 | 2003 | 1718 | 0.040 |
Why?
|
| Diarrhea | 2 | 2011 | 182 | 0.030 |
Why?
|
| Physicians | 1 | 2003 | 673 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2016 | 138 | 0.030 |
Why?
|
| Everolimus | 1 | 2015 | 40 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 266 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2016 | 278 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 567 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 357 | 0.030 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2015 | 70 | 0.030 |
Why?
|
| Disease Progression | 2 | 2015 | 1531 | 0.030 |
Why?
|
| Research | 1 | 2016 | 253 | 0.030 |
Why?
|
| Caregivers | 1 | 2016 | 151 | 0.030 |
Why?
|
| Bone Resorption | 3 | 1990 | 41 | 0.030 |
Why?
|
| Neutropenia | 1 | 2015 | 215 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2022 | 4210 | 0.030 |
Why?
|
| Transplantation, Heterologous | 3 | 2010 | 363 | 0.030 |
Why?
|
| Heterografts | 1 | 2014 | 98 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2016 | 237 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 857 | 0.030 |
Why?
|
| Gene Transfer Techniques | 1 | 2014 | 152 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2015 | 182 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 812 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 943 | 0.030 |
Why?
|
| Disease Management | 1 | 2016 | 327 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 322 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 238 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1994 | 244 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2017 | 8475 | 0.030 |
Why?
|
| Climacteric | 1 | 1993 | 4 | 0.030 |
Why?
|
| Goserelin | 1 | 1993 | 6 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 853 | 0.030 |
Why?
|
| Osteoclasts | 2 | 1990 | 33 | 0.030 |
Why?
|
| Leuprolide | 1 | 1993 | 30 | 0.030 |
Why?
|
| Clonidine | 1 | 1993 | 37 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 454 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 860 | 0.030 |
Why?
|
| Drug Resistance | 1 | 1994 | 256 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2015 | 1106 | 0.030 |
Why?
|
| Symptom Assessment | 1 | 2013 | 65 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2013 | 252 | 0.030 |
Why?
|
| Triazoles | 1 | 2013 | 96 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 3636 | 0.030 |
Why?
|
| Kidney | 2 | 1989 | 1241 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1804 | 0.030 |
Why?
|
| United States Department of Defense | 1 | 2011 | 5 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2011 | 20 | 0.030 |
Why?
|
| Age Factors | 1 | 2016 | 1849 | 0.030 |
Why?
|
| Urology | 1 | 2013 | 110 | 0.030 |
Why?
|
| Indazoles | 1 | 2011 | 68 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 1993 | 1041 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2003 | 1961 | 0.020 |
Why?
|
| Cell Movement | 1 | 2014 | 758 | 0.020 |
Why?
|
| Universities | 1 | 2011 | 135 | 0.020 |
Why?
|
| Tissue Extracts | 1 | 1990 | 24 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2011 | 227 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2010 | 229 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2010 | 105 | 0.020 |
Why?
|
| Self Concept | 1 | 2010 | 133 | 0.020 |
Why?
|
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 1989 | 10 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2010 | 334 | 0.020 |
Why?
|
| Steroid Hydroxylases | 1 | 1989 | 14 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2013 | 359 | 0.020 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 1989 | 74 | 0.020 |
Why?
|
| Cell Division | 1 | 2010 | 696 | 0.020 |
Why?
|
| Estradiol | 1 | 2010 | 252 | 0.020 |
Why?
|
| Prognosis | 1 | 2016 | 3674 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 1753 | 0.020 |
Why?
|
| Weight Loss | 1 | 2010 | 229 | 0.020 |
Why?
|
| Data Collection | 1 | 2010 | 372 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2010 | 321 | 0.020 |
Why?
|
| Oncogenes | 1 | 1988 | 88 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2010 | 458 | 0.020 |
Why?
|
| Gene Amplification | 1 | 1988 | 131 | 0.020 |
Why?
|
| Laryngeal Neoplasms | 1 | 1988 | 89 | 0.020 |
Why?
|
| Calcitriol | 1 | 1989 | 174 | 0.020 |
Why?
|
| Anxiety | 1 | 2010 | 287 | 0.020 |
Why?
|
| Carnitine | 1 | 1987 | 14 | 0.020 |
Why?
|
| Thymectomy | 1 | 1987 | 31 | 0.020 |
Why?
|
| Risk Factors | 1 | 2018 | 5416 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2013 | 1578 | 0.020 |
Why?
|
| Chicago | 1 | 2011 | 1379 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2007 | 181 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 297 | 0.020 |
Why?
|
| ROC Curve | 1 | 2007 | 752 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2010 | 1197 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 1988 | 532 | 0.020 |
Why?
|
| Doxorubicin | 1 | 1985 | 295 | 0.020 |
Why?
|
| Proteins | 1 | 1990 | 777 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2007 | 1019 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2008 | 1823 | 0.010 |
Why?
|
| Safety | 1 | 2003 | 152 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2003 | 270 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 2000 | 79 | 0.010 |
Why?
|
| Parathyroid Hormone-Related Protein | 2 | 1990 | 12 | 0.010 |
Why?
|
| Cause of Death | 1 | 2000 | 277 | 0.010 |
Why?
|
| Immunoassay | 1 | 1999 | 92 | 0.010 |
Why?
|
| Microscopy, Electron | 2 | 1990 | 503 | 0.010 |
Why?
|
| Remission Induction | 1 | 2000 | 722 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 1985 | 1052 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2000 | 839 | 0.010 |
Why?
|
| Reference Values | 2 | 1989 | 674 | 0.010 |
Why?
|
| Phosphorus | 2 | 1989 | 118 | 0.010 |
Why?
|
| Venous Thrombosis | 1 | 1999 | 243 | 0.010 |
Why?
|
| Adolescent | 1 | 2007 | 8979 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2000 | 1313 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1993 | 429 | 0.010 |
Why?
|
| Pregnancy | 1 | 1999 | 2893 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 1999 | 806 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 1993 | 552 | 0.010 |
Why?
|
| Osteoblasts | 1 | 1990 | 95 | 0.010 |
Why?
|
| Teriparatide | 1 | 1988 | 3 | 0.010 |
Why?
|
| Osteocytes | 1 | 1988 | 9 | 0.010 |
Why?
|
| Cattle | 1 | 1988 | 376 | 0.000 |
Why?
|
| Cyclic AMP | 1 | 1988 | 273 | 0.000 |
Why?
|
| Minerals | 1 | 1984 | 22 | 0.000 |
Why?
|
| Magnesium | 1 | 1984 | 177 | 0.000 |
Why?
|
| Spine | 1 | 1984 | 102 | 0.000 |
Why?
|